nature portfolio

Corresponding author(s):	Caroline Gutjahr, Moxian Chen, Jianhua Zhang
Last updated by author(s):	Dec 6, 2021

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

<u> </u>				
St	at	TS.	tι	$^{\sim}$

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficien AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
Software and code
Policy information about <u>availability of computer code</u>
Data collection Zeiss ZEN 2020 v3.3 & Swift Easy View (AM imaging); CFX Maestro Software 2.0 (RT-qPCR)
Data analysis SALMON 0.7.0, and Bioconductor 3.13 (RNASeq); TRIM-Galore 0.6.4, BWA-MEM2, samtools-1.14, bedtools 2.29.2, deepTools 2.0, MACS2, IGV 2.8.9 (ChIP-Seq); GraphPad Prism v8.0 (AM colonization, qPCR, transactivation assay, field soil assay), Clustal Omega 1.2.4 (Phylogenetic analysis)
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our <u>policy</u>

The RNAseq data generated in this study have been deposited in the SRA database under BioProject accession code PRJNA735781: https://Dataview.ncbi.nlm.nih.gov/object/PRJNA735781?reviewer=3cvg1gepckl1es04rfuslpiad2

The ChIP-Seq data generated in this study have been deposited in the SRA database under BioProject accession code PRJNA735744:

https://Dataview.ncbi.nlm.nih.gov/object/PRJNA735744?reviewer=hjvlce636jnenf75q90rcce5a0 Source data are provided with this paper. Rice reference transcriptome was downloaded from publicly accessible Phytozome v12 database (https://phytozome.jgi.doe.gov/pz/portal.html).			
ield-spe	ecific reporting		
Life sciences	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. Behavioural & social sciences		
	sclose on these points even when the disclosure is negative.		
Sample size	No statistical analyses were performed to predetermine sample size in any of the experiment. Sample sizes were chosen according to the standard for these types of analyses. In most experiments, 3-5 biological replicates (represented by one plant each) were used. In transactivation assays, 11-12 biological replicates were collected. These represent 11-12 independent Agrobacterium infiltrations, one per leaf into leaves of 4 individual plants. In ChIP-Seq, 2 independent replicate experiments were conducted, which is currently the minimum standard sample size for ChIP-Seq assays.		
Data exclusions	No data presented or mentioned in this work has been excluded.		
Replication	For lab-based AM phenotyping and field soil assay, 3-5 biological replicates each from different plants from same experiment were used. For qPCR, 3 biological replicates from same experiment were used. For RNASeq, 3 biological replicates from same experiment were used. For transactivation assays, 11-12 biological replicates from 4 individual plants from same experiment were used. For ChIP-Seq, 2 biological replicates collected from 2 different replicate experiments were used. The experiment in field soil confirms the experiments performed in the laboratory and therefore act as an independent confirmation.		
Randomization	Samples were randomly allocated to each group and treated.		
Blinding	For AM colonization quantification, investigators were blinded. For qPCR, RNASeq and ChIP-Seq, an unbiased quantification was made and hence investigators were not blinded. For qPCR, RNASeq and ChIP-seq, templates were prepared by the first-author and an organized pipetting scheme was necessary not to mix up different samples. Furthermore, transcript or DNA quantity in qPCR, RNASeq and ChIP-seq was measured by a machine, so there was no influence of the experimenter.		
<u> </u>	g for specific materials, systems and methods on from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,		
·	ted is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & exp	perimental systems Methods		
n/a Involved in th	' ' _ _ ' ' ' _ _ ' ' _ ' _ ' _ ' _ ' _ '		
Eukaryotic			
	logy and archaeology MRI-based neuroimaging		
	nd other organisms search participants		
Clinical dat			
	esearch of concern		

Antibodies

Antibodies used

Anti-Flag (F1804, Sigma); IgG (ab171870, Abcam); Antibody dilution used for each antibody was 1: 100

Validation

Both the Anti-FLAG and IgG antibody as described above were previously used (Reference 17; Wang et al., 2014) for ChIP assays involving the same transgenic line 35S-PHR2-FLAG as used in this study.

ChIP-sea

Data deposition

Confirm that both raw and final processed data have been deposited in a public database such as GEO.

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

May remain private before publication.

ChIP-Seq data is submitted to BioProject PRJNA735744: https://Dataview.ncbi.nlm.nih.gov/object/PRJNA735744?reviewer=hjvlce636jnenf75q90rcce5a0

Files in database submission

ChIP-Seq raw data has been submitted to NCBI SRA and contains 4 fastq files (2 biological replicates of FLAG-IP and INPUT each).

Genome browser session

NOT USED

(e.g. UCSC)

Methodology

Replicates Each biological replicate was collected from a different replicate experiment.

Sequencing depth

150bp paired-end reads were collected for each sample. In total, around 53 million reads were obtained for each sample out of which 37 million reads uniquely mapped to rice reference genome in BWA-MEM2.

Antibodies

Anti-FLAG (F1804, Sigma)

Peak calling parameters

MACS2 was used for peak calling

Data quality

Data quality assessment process has been mentioned in the METHODS section in detail

Software

TRIM-Galore 0.6.4, BWA-MEM2, samtools-1.14, bedtools 2.29.2, deepTools 2.0, MACS2, IGV 2.8.9 (ChIP-Seq)